FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040953345> ?p ?o ?g. }

• W2040953345 endingPage "174" @default.
• W2040953345 startingPage "154" @default.
• W2040953345 abstract "A preceding study had shown that mice bearing sarcoma-180 incorporated 40V0 more 5-125I-2′-deoxyuridine (125I-UdR) into DNA of long lived cells outside the tumor than normal controls. This was expressed by external whole body measurements of living animals over a period of 4 weeks following one single intravenous injection of 125I-UdR. This paper analyses the extent to which various tumor-free organs of the tumor bearing host contribute to the increased 125I-UdR incorporation. Adult virgin albino NMRI mice bearing 4 days old implants of sarcoma-180 received a single i.v. injection of 125I-UdR in order to label the DNA of proliferating cells in the whole body. I-UdR not incorporated within about 1 hour after injection is rapidly catabolized and excreted when the animals are kept on 0.1% NaI drinking water in order to block the pool of inorganic iodine. At day 1, 6, 10 and 15 after application of I-UdR 10 mice were assayed in a whole body counter and sacrificed by cervical luxation; the activity was determined in liver, spleen, kidneys, lungs, femora, thymus, mesenteric lymphnodes, and skin, also in the dissected tumor. The organ activities were compared with those of normal mice. It was confirmed that from day 6 to day 15 after I-UdR injection the whole body activity of tumor carriers, after resection of the tumor, was about 40% higher than in controls (Fig. 3). 1 to 15 days after injection of 125I-UdR the liver remained approximately 6–7 times more active in the tumor bearing than in normal mice. In the spleen, the activity in tumor carriers at day 1 was 5–6 times higher; thereafter, the difference declined to about 2.5–3.0 and remained so until the end of the observations (Fig. 1). In kidney and lung of the tumor carriers the activity at day I was elevated by a factor of about 2.8. The difference remained nearly constant in the kidney; yet in the lungs it converged to a factor of about 1.3 at day 15. In the femora of tumor carriers the activity content was elevated by a factor of 2.3 above that of controls on day 1. Thereafter, there was no difference in activity between the two groups. No significant difference between tumor bearing and normal mice was found in thymus, mesenteric lymphnodes, and skin (Fig. 2). On the first day after application of the tracer liver and spleen of tumor carriers accounted for 50% of the activity increase in whole body measurements, kidneys and lungs for about 6% and the femora for nearly 7%. The initial contribution of the entire bone marrow was estimated to be approximately 30%. Later than day 1 the liver of the tumor carriers contributed 50–53% to the difference of whole body counts between tumor carriers and controls, the spleen about 15%, the kidneys 6–7%, and the lungs 1.5–3% (Tab. 2). There was no difference in the activity of femora between tumor carriers and controls later than day 1. After removal of the quoted organs and of the tumor the remaining bodies of tumor-bearing and normal mice showed virtually the same activity (Fig. 4). The rate of loss of activity from day 1 to day 6 greatly varied in different organs; yet it was similar in all these organs from day 10 to day 15 amounting to approximately 5–6% in tumor carriers as well as in controls. The observed data obtained with 125I-UdR are in good agreement with reports from different laboratories describing in tumor bearing rodents an increased rate of incorporation of DNA precursors in liver, spleen and kidneys; an increased DNA content in these organs and in the lungs due to an increase in DNA synthetising cells was found (Tab. 3). During the second week after injection of 125I-UdR the rate of daily loss of activity related to cells characterized by a relatively long life span was observed nearly equal in various organs and in the whole body of tumor carriers as well as of normal mice. It amounted to 5–6% per day. The calculated turnover time of about 60 days is similar to that reported for macrophages. This agrees with the data from the literature indicating an increased number of macrophages in organs of tumor carriers, including spleen, liver and precursors in cultures of bone marrow. The results suggest that the increased binding of 125I-UdR in cells characterized by a low rate of proliferation in various organs and in the whole body of tumor carriers expresses a cellular reaction to the presence of the tumor. Stimulation of proliferation of elements of the reticulo-endothelial system must be seriously considered. In conjunction with previous reports from this laboratory the present data indicate that it is possible to observe the response of the host to the tumor by non-invasive, external measurements of the living mouse. Da vorausgegangene externe Ganzkörpermessungen lebender NMRI-Mäuse eine erhöhte Einbaurate des DNA-Vorläufers J-UdR in relativ langlebige proliferierende Zellpopulationen im Normalgewebe bei Tumorträgern gegenüber Kontrollen erkennen ließen, wurden parallel zum Ganzkörper die Aktivitäten von Leber, Milz, Lungen, Knochenmark, Thymus, mesenterialen Lymphknoten und Haut 15 Tage lang nach Injektion von 125J-UdR in Tumorträgern und Kontrollen bestimmt. Als Tumor diente Sarkom-180. Die organspezifischen Untersuchungen zeigten bei Tumorträgern einen erhöhten Einbau des Vorläufers in die proliferierenden Zellpopulationen mit relativ niedriger Umsatzrate in Leber, Milz und Nieren. Zu der beobachteten Differenz der Ganzkörperaktivität zwischen Tumorträgern und Kontrollen 6 bis 15 Tage nach Injektion von 125J-UdR tragen nach Abzug der tumorgebundenen Aktivität die Leber etwa die Hälfte, die Milz etwa 17% und Nieren und Lungen zusammen etwa 9% bei. Die Versuchsergebnisse legen den Schluß nahe, daß der erhöhten Proliferationsrate von Zellpopulationen mit relativ langer Lebensdauer im Normalgewebe von Tumorträgern u. a. eine Reaktion des RES zugrunde liegt und vermutlich eine Immunreaktion gegen tumorassoziierte und/oder unspezifische Transplantationsantigene angezeigt wird. Die Erhöhung der DNA-Synthese in langlebigen normalen Zellen tumortragender, metastasenfreier Mäuse läßt sich nach Injektion eines markierten Vorläufers am lebenden Tier mittels Ganzkörpermessung erfassen." @default.
• W2040953345 created "2016-06-24" @default.
• W2040953345 creator A5011394231 @default.
• W2040953345 creator A5021631579 @default.
• W2040953345 creator A5026558846 @default.
• W2040953345 creator A5049114005 @default.
• W2040953345 date "1977-05-01" @default.
• W2040953345 modified "2023-09-26" @default.
• W2040953345 title "DNA Turnover in Metastasis-free Organs of Tumor Bearing Mice; Influence on Whole Body Measurements with 125I-UdR" @default.
• W2040953345 cites W110867467 @default.
• W2040953345 cites W1430627215 @default.
• W2040953345 cites W1483864201 @default.
• W2040953345 cites W1484081569 @default.
• W2040953345 cites W1554509789 @default.
• W2040953345 cites W1556860219 @default.
• W2040953345 cites W1589587903 @default.
• W2040953345 cites W1598962616 @default.
• W2040953345 cites W1600017467 @default.
• W2040953345 cites W1608808731 @default.
• W2040953345 cites W1643953828 @default.
• W2040953345 cites W172515195 @default.
• W2040953345 cites W1757025880 @default.
• W2040953345 cites W1760495269 @default.
• W2040953345 cites W1929731514 @default.
• W2040953345 cites W1931829426 @default.
• W2040953345 cites W1949110470 @default.
• W2040953345 cites W1973143844 @default.
• W2040953345 cites W1982269890 @default.
• W2040953345 cites W1988575745 @default.
• W2040953345 cites W1989229803 @default.
• W2040953345 cites W1995260125 @default.
• W2040953345 cites W2015864594 @default.
• W2040953345 cites W2019595431 @default.
• W2040953345 cites W2027270364 @default.
• W2040953345 cites W2038264983 @default.
• W2040953345 cites W2048060728 @default.
• W2040953345 cites W2058170387 @default.
• W2040953345 cites W2102431840 @default.
• W2040953345 cites W2124803821 @default.
• W2040953345 cites W2125238372 @default.
• W2040953345 cites W2137474508 @default.
• W2040953345 cites W2140368912 @default.
• W2040953345 cites W2239742308 @default.
• W2040953345 cites W2302494602 @default.
• W2040953345 cites W2330345735 @default.
• W2040953345 cites W2404918313 @default.
• W2040953345 cites W2406727789 @default.
• W2040953345 cites W2409886683 @default.
• W2040953345 cites W2410127923 @default.
• W2040953345 cites W2415197146 @default.
• W2040953345 cites W2417441042 @default.
• W2040953345 cites W2463682041 @default.
• W2040953345 cites W2465732378 @default.
• W2040953345 cites W2727286528 @default.
• W2040953345 cites W2894263709 @default.
• W2040953345 cites W2897149470 @default.
• W2040953345 cites W74609980 @default.
• W2040953345 cites W1669625243 @default.
• W2040953345 doi "https://doi.org/10.1016/s0005-8165(77)80022-x" @default.
• W2040953345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/889561" @default.
• W2040953345 hasPublicationYear "1977" @default.
• W2040953345 type Work @default.
• W2040953345 sameAs 2040953345 @default.
• W2040953345 citedByCount "0" @default.
• W2040953345 crossrefType "journal-article" @default.
• W2040953345 hasAuthorship W2040953345A5011394231 @default.
• W2040953345 hasAuthorship W2040953345A5021631579 @default.
• W2040953345 hasAuthorship W2040953345A5026558846 @default.
• W2040953345 hasAuthorship W2040953345A5049114005 @default.
• W2040953345 hasConcept C121608353 @default.
• W2040953345 hasConcept C126322002 @default.
• W2040953345 hasConcept C134018914 @default.
• W2040953345 hasConcept C142724271 @default.
• W2040953345 hasConcept C185592680 @default.
• W2040953345 hasConcept C2778256501 @default.
• W2040953345 hasConcept C2779013556 @default.
• W2040953345 hasConcept C2780931953 @default.
• W2040953345 hasConcept C71924100 @default.
• W2040953345 hasConcept C86803240 @default.
• W2040953345 hasConceptScore W2040953345C121608353 @default.
• W2040953345 hasConceptScore W2040953345C126322002 @default.
• W2040953345 hasConceptScore W2040953345C134018914 @default.
• W2040953345 hasConceptScore W2040953345C142724271 @default.
• W2040953345 hasConceptScore W2040953345C185592680 @default.
• W2040953345 hasConceptScore W2040953345C2778256501 @default.
• W2040953345 hasConceptScore W2040953345C2779013556 @default.
• W2040953345 hasConceptScore W2040953345C2780931953 @default.
• W2040953345 hasConceptScore W2040953345C71924100 @default.
• W2040953345 hasConceptScore W2040953345C86803240 @default.
• W2040953345 hasIssue "2" @default.
• W2040953345 hasLocation W20409533451 @default.
• W2040953345 hasLocation W20409533452 @default.
• W2040953345 hasOpenAccess W2040953345 @default.
• W2040953345 hasPrimaryLocation W20409533451 @default.
• W2040953345 hasRelatedWork W1966504330 @default.
• W2040953345 hasRelatedWork W1974041167 @default.
• W2040953345 hasRelatedWork W1979139803 @default.
• W2040953345 hasRelatedWork W2030889776 @default.

• next